All In Biotech

Drug Trial Radar · NCT06580041

Precision Care for Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 12, 2024

Primary completion

Sep 1, 2029

Study completion Sep 1, 2029

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.

Conditions

  • Major Depressive Disorder
  • Depression
  • Depressive Disorder, Major

Interventions

  • PramipexoleDrug

    CAU plan modified to include a trial of pramipexole.

  • MethylphenidateDrug

    CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).

  • PhenelzineDrug

    CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).

  • Mindfulness-based Stress Sensitivity Therapy (MBSST)Behavioral

    CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.

  • Complicated Grief Treatment (CGT)Behavioral

    CAU plan modified to include a trial of CGT.

  • Care as usual (CAU) planOther

    Unmodified CAU plan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) scoreTime frame: Up to 24 weeks after randomization.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.